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OBJECTIVES This study evaluates the hemodynamic, bioenergetic and cytoprotective effects of urocortin
(Ucn) in the isolated rat heart exposed to ischemia (I)/reperfusion (R).
BACKGROUND We have previously demonstrated that administration of exogenous Ucn reduces infarct size
in ischemic-reperfused rat hearts.
METHODS Urocortin 108M was added to the perfusate before I, before I and during R, and during R
alone in the isolated pulsed rat heart exposed to 35 min I followed by 60 min R.
RESULTS Partial to complete recovery of diastolic pressure and developed pressure was seen irrespective
of when Ucn was perfused. In particular, beneficial effects are observed when Ucn is only
given during R. Urocortin given only before I, and before I and over R, although not during
R alone, also produces significant recovery of high-energy phosphate pools. In each group,
improvement in ventricular function is associated with reduction both in myocardial damage,
assessed by creatine phosphokinase release, and in endothelial cell and cardiomyocyte
apoptosis, assessed by caspase 3 activity and fluorescent-based terminal deoxynucleotidyl
transferase mediated nick end labelling enhanced with counterstains. These improvements in
ventricular performance, bioenergetics and cell survival are not secondary to any inotropic
effects of Ucn.
CONCLUSIONS This is the first report to show enhanced cardiac function induced by Ucn during I/R. Because
the cytoprotective and functional benefits are still produced when Ucn is given only at R,
these data suggest that Ucn may be useful clinically in the management of myocardial
infarction. (J Am Coll Cardiol 2002;40:155–61) © 2002 by the American College of
Cardiology Foundation
Myocardial ischemia/reperfusion (I/R) triggers a cascade of
key pathogenetic cellular events such as massive influx of
calcium, mitochondrial damage and rapid depletion of high
energy stores, leading to both necrotic and apoptotic cell
death. In addition, the mechanical efficiency of the heart is
compromised, with a fall in developed pressure (DP) and
progressive increases of diastolic pressure (dP) throughout I
and R. The degree of myocyte death and the severity of the
hemodynamic consequences are major determinants of the
clinical outcome of I/R, and therapies for myocardial
infarction must both improve cell survival and promote
mechanical recovery.
Urocortin (Ucn) is a 40 amino acid member of the
corticotropin-releasing hormone family, initially character-
ized in rat brain (1). Subsequently, Ucn expression has also
been described in a number of other sites including the
placenta (2), the immune system (3), the gastrointestinal
tract (4) and the cardiovascular system (5). Urocortin and
other members of the family exert their physiologic effects
through binding to two G-protein coupled receptors
(corticotropin-releasing hormone-R1 and -R2), both of
which can be expressed in alternatively spliced forms.
Corticotropin-releasing hormone-R2 has at least 10-fold
higher affinity for Ucn than for corticotropin-releasing
hormone and is the only such receptor found in the heart
(6,7). This coexpression in the heart of corticotropin-
releasing hormone-R2 together with its preferred Ucn
ligand suggests that cardiac Ucn may exert autocrine/
paracrine physiologic effects on the heart.
Several studies have, indeed, shown effects of exogenously
administered corticotropin-releasing hormone-like peptides
on cardiac function, although these may depend on the
route of administration. For example, heart rate, cardiac
output and mean arterial pressure are increased when
corticotropin-releasing hormone is given into the cerebral
ventricles (8–10), although mean arterial pressure is de-
creased by intravenous injection (11,12). In contrast, intra-
venous injection of Ucn into conscious sheep increases mean
arterial pressure, together with heart rate, cardiac output
and coronary blood flow (13). However, because both
corticotropin-releasing hormone (14) and Ucn (15) have
been shown to stimulate atrial natriuretic peptide release
from cultured neonatal rat cardiomyocyte (CM), some of
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their physiologic effects may be indirect. In contrast, Ucn
perfused through the isolated rat heart has a coronary
vasodilator effect and enhances left ventricular pressure (16),
and this effect must be atrial natriuretic peptide-
independent. In agreement with the presumed role of
corticotropin-releasing hormone-R2 in mediating the ef-
fects of Ucn on the heart, intravenous Ucn does not affect
cardiac function in corticotropin-releasing hormone-R2
knockout mice (17).
We have previously reported that exposure of cultured
neonatal CM to I/R increased Ucn messenger ribonucleic
acid abundance and release of Ucn peptide (18). The
addition of exogenous Ucn reduced necrotic and apoptotic
myocyte death after simulated I/R in cultured CM, and also
reduced infarct size in the Langendorff perfused heart
exposed to I/R, even when addition of the peptide was
delayed until the onset of R (19). In the present study, we
have examined these cytoprotective effects in more detail
and asked whether the beneficial effects of Ucn on myocyte
survival are associated with an equally marked improvement
in functional recovery. The isolated heart has been preferred
as it allows assessment of the direct cardioprotective effects
of Ucn in the absence of interfering peripheral hemody-
namic and neurohumoral alterations. We demonstrate that
Ucn exerts a cytoprotective action that is independent from
a negative inotropic effect and is associated with both
recovery of cardiac performance and reduced depletion of
endogenous high-energy phosphates.
METHODS
Animal model. Male Sprague-Dawley rats weighing 300 g
to 350 g were anesthetized by sodium pentobarbital (6 mg
kg1 administered intraperitoneally) and sacrificed by de-
capitation. The heart were removed, immersed in an ice-
cold modified Krebs-Hensleit buffer solution (BS) and
subsequently perfused by the nonrecirculating Langendorff
technique at a constant flow of 11 ml/min as previously
described (20). The heart rate was continuously maintained
at 300 beats/min by electrical pacing, and the left ventricular
wall was kept at the steady temperature of 37°C. After a
period of stabilization of at least 30 min, the isolated hearts
were randomly divided into six groups of six hearts each.
Group A (I/R control) and three treated groups (B, C and
D) were continuously perfused for 60 min, made globally
ischemic for 35 min and reperfused for 60 min. Treated
hearts were then perfused with Ucn dissolved in the perfus-
ate at the dose of 108 M either 60 min before I alone
(group B), 60 min before I and during R (group C) or
during R alone (group D). Finally, two other groups (E
and F) were simply perfused for 2 h with either BS or Ucn
(108 M).
Left ventricular pressure. To obtain an isovolumetrically
beating preparation, a latex balloon filled with saline,
connected by a catheter to a Statham transducer (P 23 XL,
VWR International, Milan, Italy), was inserted into the left
ventricle through an atriotomy and secured by a suture
around the atrioventricular groove. The balloon was inflated
to provide an end-diastolic pressure 1.0 mm Hg (20).
Assay of creatine phosphokinase in the coronary efflu-
ent. During each perfusion, the coronary effluent was
collected at different time points in chilled glass vials and
promptly assayed for creatine phosphokinase (CPK) activity
by spectrophotometry, as previously reported (21).
Assay of high-energy phosphates. After each perfusion,
the hearts were freeze-clamped with aluminum tongues
precooled in liquid nitrogen. Separation and quantification
of adenosine triphosphate (ATP) and creatine phosphate
were performed in ventricular tissue extracts by using a
reversed-phase 3-m C18 column, as previously described
(22).
Caspase 3 (C3) activity measurement (aspartyl glutamyl-
valylaspartic acid cleavage enzyme assay). Cardiac activa-
tion of C3 was evaluated in tissue extracts using a commer-
cial kit (caspase-3/CPP32 Fluorometric Assay Kit,
Biovision, Mountain View, California) with the following
changes to the recommended protocol. Cardiac ventricular
tissue from each group was placed in ice-cold lysis buffer and
subsequently homogenized. The homogenates were centri-
fuged at 750  g for 5 min at 4°C. Supernatants were then
centrifuged at 10,000  g for 15 min at 4°C. Enzyme
reactions were performed with 300 g of cytosolic pro-
teins per assay and a final concentration of 50 M aspartyl
glutamylvalylaspartic acid–7-amino-4-trifluoromethyl cour-
marin. Samples were read in a fluorimeter equipped with a
400-nm excitation and a 505-nm emission filter. Fold-
increase in C3 activity was determined by comparing fluo-
rescence of 7-amino-4-trifluoromethyl courmarin in control
and treated hearts with BS perfused control.
Preparation and staining of sections. Serial 5 m sections
were cut from paraffin blocks and, after dewaxing and
heat-mediated antigen retrieval, stained with terminal de-
oxynucleotidyl transferase mediated nick end labeling
(TUNEL) reagents and propidium iodide. In other sec-
tions, TUNEL staining was combined with anti-desmin or
von Willebrand factor antibodies to selectively identify CM
Abbreviations and Acronyms
ATP  adenosine triphosphate
BS  buffer solution
CF  coronary flow
CM  cardiomyocyte
CPK  creatine phosphokinase
C3  caspase 3
dP  diastolic pressure
DP  developed pressure
EC  endothelial cell
I/R  ischemia/reperfusion
TUNEL  terminal deoxynucleotidyl transferase
mediated nick end labelling
Ucn  urocortin
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and endothelial cells (EC), respectively (23,24). After wash-
ing, slides were mounted and examined by confocal fluo-
rescent microscopy as described before.
Data are expressed as the means of 12 to 15 high power
fields  SD.
Statistics. Analysis of covariance, with time as the covari-
ate and post-hoc analyses were used to test the principal
component with contrast. The Bonferroni correction was
then applied and p values 0.05 were considered signifi-
cant.
RESULTS
Mechanical function. Developed pressure and dP in con-
trol and treated hearts exposed to I/R are shown in Figure 1.
Untreated hearts showed a constant DP (103.3 9.8 mm Hg)
with no change in dP during stabilization and aerobic
perfusion (Fig. 1a). Abolition of the coronary flow (CF)
caused a rapid decline in DP. Diastolic pressure started to
rise 10 min after I (27.7  8.2 mm Hg) and progressively
increased during the ischemic phase, reaching 30.7  5.3
mm Hg at the end of I. With restoration of CF, dP was
further augmented. After 5 min R, it reached a peak of
55.7  12.1 mm Hg and then slowly decreased to 51.0 
11.3 mm Hg at the completion of R. In addition, the I/R
control group showed only limited recovery of DP, which
increased to 64.5  8.3 mm Hg by the end of R.
Administration of Ucn during aerobic perfusion had no
effect on the hemodynamics of isolated hearts, apart from a
transient, nonsignificant increase in DP during the first
phase of infusion (p  0.05 vs. I/R control, Fig. 1b).
However, in the hearts treated with Ucn before I alone (Fig.
1b) as well as before I and during R (Fig. 1c), Ucn
significantly reduced the progressive rise of dP observed
during I (14.3  3.2 mm Hg and 13.5  3.2 mm Hg in
groups B and C, respectively, after 30 min I, p  0.05 vs.
I/R control), and, in both groups, recovery of dP after R was
complete. In the same groups (B and C, Figs. 1b and 1c),
Ucn produced a rapid recovery of DP, which began after
only 1 min of R (44.0  6.9 mm Hg and 52.8  7.2 mm
Hg, respectively; p  0.05 vs. I/R control), and which
progressively improved with partial (group B) and complete
(group C) normalization (86.0  7.9 mm Hg and 110.4 
12.8 mm Hg, respectively; p  0.001 vs. I/R control) at the
end of R. Isolated hearts from group D, treated with Ucn
only during R (Fig. 1d), also showed a significantly im-
proved post ischemic DP recovery (82.3 8.3 mm Hg; p
0.001 at the end of R) with progressively diminishing dP
values over the length of R (29.1  5.3 at 10 min; p  0.05
vs. I/R control and 25.3  4.1 at 60 min: p  0.001 vs. I/R
control).
Hence, Ucn has no effect on DP and dP in control
perfused hearts, but ameliorates the fall in DP and the rise
in dP observed during I/R, when given before the onset of
the ischemic insult. Pre- and postischemic treatment with
Ucn produces complete recovery of dP and DP, while
preischemic treatment only results in normalization of dP
and partial restoration of DP, during R. Progressive but
partial recovery of both dP and DP is also seen when Ucn is
only given after restoration of the flow.
CPK release. Figure 2a shows the effects of Ucn on
R-induced release of CPK, a typical index of cell damage.
During the aerobic preischemic period, only small amounts
of CPK were released. Urocortin did not affect the release
curve of the enzyme. In control hearts exposed to I/R, R
resulted in marked and sustained release of CPK, which
peaked at 30 min from the restoration of flow (1,785  88
at 30 min R). Urocortin administered both 60 min before I
alone, and before I and during R significantly attenuated the
cardiac CPK release (620  46 and 510  43 after 30 min
R, respectively; p  0.001 vs. I/R control). Consistent with
the hemodynamic findings, the release of CPK into the CF
was reduced even when Ucn treatment was performed only
during R (1,005 56; p 0.05 vs. I/R control). Therefore,
Ucn given before I alone, before I and during R, and during
R alone significantly reduces CPK release during the reper-
fusion phase.
ATP and creatine phosphate tissue reserves. The cardiac
levels of ATP and creatine phosphate assessed after 2 h of
aerobic BS perfusion are reported in Figure 2b. The infusion
of Ucn over the aerobic phase did not modify the reservoir
of both high energy molecules. In ischemic-reperfused
control hearts, the endogenous stores of ATP and creatine
phosphate evaluated at the end of I showed a dramatic
decline (5.4  0.9 and 4.95  0.7, respectively), which R
failed to normalize (6.6  1.3 and 6.3  1.1, respectively).
Preischemic infusion of Ucn reduced the tissue drop of ATP
and creatine phosphate levels measured both at the end of I
(12.5  2.2 and 11.6  1.8, respectively; p  0.05 vs. I/R
control) and R (13.4 2.4 and 18.7 3.5, respectively; p
0.001 vs. I/R control). Adenosine triphosphate and creatine
phosphate contents were maximally preserved in hearts
receiving Ucn both before I and after R (16.2  2.8 and
25.5  4.3, respectively; p  0.0001 vs. I/R control). The
administration of Ucn only during R resulted in a small
recovery of tissue ATP and creatine phosphate contents,
which failed to reach reach statistical significance (7.9 1.8
and 7.1  1.5, respectively; p  0.05). Hence, Ucn
administered before I alone and before I and during R
partially restore ATP and creatine phosphate tissue levels
both after I and R. Urocortin only given during R has no
significant effect on tissue reserves of both high energy
molecules measured after R.
Evaluation of C3 activity in tissue extracts. Apoptosis is
one form of cell death after I/R injury and is mediated
through sequential activation of the caspase cascade.
Caspase 3 is one of the terminal effector caspases, which
cleaves substrates important for cell survival, and the level of
C3 activity is, therefore, an important marker of the level of
apoptosis. We, therefore, used an enzymatic assay to mea-
sure the activity of C3 at the end of R in each of the
treatment groups (Fig. 2c). We also employed an antibody
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Figure 1. Effects of urocortin (Ucn) on developed pressure (DP) and diastolic pressure (dP) during ischemia/reperfusion (I/R) in the isolated rat heart. Developed pressure and dP in control heart exposed
to I/R are shown in a; changes in DP and dP induced by Ucn given before I, before and after R, and over R alone are reported in b, c and d, respectively. Solid triangle  DP; open square  dP.
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Figure 2. (a) Effects of urocortin (Ucn) administered before ischemia (I) (Ucn pre-I), before and after I (Ucn I/reperfusion) (R) and during R only (Ucn R) on the postischemic release of creatine phosphokinase
(CPK). Creatine phosphokinase release by control (CTL) hearts subjected to I/R is shown by CTL I/R. (b) Effects of Ucn on adenosine triphosphate (ATP) (Solid bars) and creatine phosphate (open bars)
levels at the end of I (end I) and at the end of R (end R) when given before I (Ucn pre-I), before I and during R (Ucn I/R) and only over R (Ucn R). Values for buffer (BS perf) and Ucn perfused (Ucn
inf) hearts as well as for non-Ucn-treated hearts exposed to I/R (CTL I/R) are also shown. (c) Numbers of cells positive for cleaved active caspase 3 (C3) (bars) and tissue levels of C3 activity (line) assessed
at the end of I/R in hearts perfused with buffer (P), infused with Ucn (P  Ucn), exposed to I/R (control) and treated with Ucn (108 M) before I (Ucn pre-I), both before and after I (Ucn I/R) and during
R alone (Ucn R). (d) Percentages of TUNEL and cleaved active C3 positive endothelial cells (EC) (open bars and open squares) and cardiomyocytes (CM) (solid bars and open circles) in the various
treatment groups. The legend for the individual groups is as described in (2c).
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specific for active, cleaved C3 to evaluate the total number
of EC and CM, which contained active C3 (Fig. 2c). The
number of positive cells is expressed as the mean of 15
neighboring high power fields.
Caspase 3 activity, and the numbers of active C3 positive
cells, were maximally reduced when Ucn was given pre-I
and before I and during R (p  0.001 vs. BS perfused
control). A significant (p  0.05) reduction in both enzyme
activity and active C3-positive cells was still observed even
when Ucn was administered only during R.
Assessment of apoptosis by TUNEL. Terminal deoxynu-
cleotidyl transferase mediated nick end labelling is a com-
monly used method for detecting the oligonucleosomal
deoxyribonucleic acid fragmentation characteristic of end-
stage apoptotic cells. We have previously shown that cells
positive for active C3 colocalize with TUNEL-positive cells
(24). Figure 2d shows the numbers of active C3 and
TUNEL-positive EC and CM in the different treatment
groups.
In agreement with our previous study (24), more EC than
CM show evidence of apoptosis after I/R as assessed by
both techniques. Preischemic treatment with Ucn produced
a highly significant reduction in these markers of apoptotic
cell death in both cell types (groups D and E: p  0.001 vs.
I/R control). Though less profound, the reduction in
apoptosis when Ucn was only given during R remained
significant (group E: p  0.001 vs. I/R control).
DISCUSSION
This study shows that administration of the endogenous
cardiac peptide, Ucn, at a dose of 108 M, reduces necrotic
and apoptotic cell death in the isolated rat heart exposed to
I/R and, in parallel, partially prevents depletion of cellular
energy stores with enhancement of ventricular function.
These beneficial effects, apart from the preservation of
myocardial high energy reservoirs, are still seen when Ucn
perfusion is performed only during R, suggesting that Ucn
may have therapeutic potential in the management of
myocardial infarction.
Experimental model. In our study, we have intentionally
used the isolated paced rat heart exposed to zero flow
ischemia in order to assess the direct effects of Ucn on the
heart without the influence of secondary peripheral effects of
the peptide. Developed pressure and dP are commonly used
methods for assessing cardiac dysfunction after I/R injury
(25) and for evaluating the efficacy of candidate cardiopro-
tective agents (26). At the 108 M concentration used, Ucn
did not show a significant inotropic effect when given before
I during the aerobic period. However, when given pre-I,
pre-I and during R and during R alone, Ucn produced
significant functional recovery.
Effect of Ucn on cell death. The degree of cardiac dys-
function after I/R injury reflects the level of myocyte injury
and death. We have previously shown, in isolated rat hearts
exposed to 35 min I, that TUNEL-positive EC appear after
5 min and TUNEL-positive CM within 1 h of R. Consis-
tent with our previous findings that Ucn given both before
and after a simulated ischemic insult in the intact rat heart
reduced infarct size (19), in the present study Ucn reduced
both CPK release and the numbers of apoptotic cells, even
when only administered during R. Urocortin administration
significantly reduces activation of C3, as well as oligonu-
cleosomal deoxyribonucleic acid fragmentation, in both EC
and CM.
Mechanisms of Ucn-mediated cardioprotection. Cell
death after injury, and the form that it takes, is largely
dependent on levels of intracellular ATP and other high
energy phosphates (27). For example, viable cells have an
ADP:ATP ratio of0.11, apoptotic cells a ratio of between
0.11 and 1.0 and necrotic cells a ratio of up to 15 (28). The
Ucn-induced recovery of ATP stores, with reduction of the
intracellular ADP:ATP ratio, might allow damaged myo-
cytes that would otherwise die by necrosis to die by the
alternative apoptotic pathway. Because necrosis, unlike ap-
optosis, is associated with release of intracellular contents
and subsequent inflammatory reaction, reduction in the
proportion of necrotic death will result in a smaller final
lesion, with functional benefit. The reduction in CPK
release produced by Ucn treatment (Fig. 2a) would be
consistent with this interpretation. Similarly, restoration of
ATP in damaged cells predisposed to apoptosis may allow
them to remain viable, again consistent with the data in
Figures 2c and 2d.
One critical role for ATP is in the cytochrome
C-mediated formation of Apaf-1/procaspase-9 complexes,
which results in the activation of the initiator caspase-9 after
mitochondrial injury (29), and we have previously shown
that caspase-9 is the only initiator caspase activated in
hypoxic neonatal cardiac myocytes (30). The partial resto-
ration of ATP and creatine phosphate levels at the end of
both I and R suggests that Ucn acts on mitochondria to
maintain the respiratory transport chain, thus preventing
mitochondrial injury. One mechanism for these mitochon-
drial effects of Ucn may be its ability to increase expression
and function of the mitochondrial KATP channel (Lawrence
et al., unpublished data, 2002), which has been implicated
in cardioprotection (31).
Study implications. The data reported here have several
important implications. First, because Ucn is an endogenous
cardiac peptide, basal levels of Ucn may determine the
degree of cell loss and functional compromise in individual
patients suffering from myocardial infarction. Second, be-
cause endogenous levels of Ucn are increased by I/R injury
(5), raised basal levels of Ucn may play a role in the
preconditioning effect. Finally, the fact that Ucn improves
both cell survival and ventricular performance even when
only given during R suggests that Ucn may be clinically
useful in the management of established infarction.
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